Physician profile
Edward P Stack
NPI 1801899885
$3,562.77
in general payments reported to CMS, 2019-2025
29 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $323 · 2021: $476 · 2022: $720 · 2023: $621 · 2024: $429 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $986.47 | 2019-2025 | Clareon, Argos, Centurion |
| Abbvie INC. | $649.47 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Alphagan P |
| Glaukos Corporation | $581.21 | 2019-2025 | Photrexa Cross-Linking Kit, Idosetr |
| Allergan, INC. | $205.41 | 2019-2022 | |
| New World Medical,INC. | $132.95 | 2019-2025 | Clearpath, Via360, Streamline |
| Tarsus Pharmaceuticals, INC. | $125.65 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $117.15 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $109.87 | 2023-2025 | Vyzulta, Miebo, Lotemax Sm |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.13 | 2019-2021 | |
| Rxsight INC | $75.40 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $65.20 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Kala Pharmaceuticals, INC. | $55.36 | 2019-2021 | |
| Thea Pharma INC. | $49.89 | 2024-2025 | Iyuzeh |
| Dompe US, INC. | $34.17 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $33.19 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $25.01 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
| Amgen INC. | $23.82 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $21.12 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $20.95 | 2019 | |
| Merz North America, INC. | $19.57 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Aerie Pharmaceuticals, INC. | $18.52 | 2019 | |
| Harrow Eye, LLC | $17.68 | 2025 | Vevye |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Biotissue Holdings INC. | $16.61 | 2025 | |
| Eyevance Pharmaceuticals LLC | $14.89 | 2021 | |
| Horizon Therapeutics Plc | $12.82 | 2023 | Tepezza |
| Eyepoint US, INC. | $12.37 | 2019 | |
| Ocular Therapeutix, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Stack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.